SCHEMBL10201237

SCHEMBL10201237

CC(C)n1nc(C(F)(F)F)cc1-c1sc(C(=O)Nc2c(F)cccc2F)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRACR2A Q9BSW2 3/20 0.42
NPY5R Q15761 1/20 0.40
IL2 P60568 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 1/20 0.39
STIM1 Q13586 3/20 0.38
ORAI1 Q96D31 3/20 0.38
P2RY1 P47900 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10201241 0.91 CRACR2A (0.40) CRACR2ANPY5RIL2HDAC3HDAC4
SCHEMBL10201240 0.89 KLKB1 (0.44) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10201255 0.89 CRACR2A (0.39) CRACR2ANPY5RIL2HDAC3HDAC4
SCHEMBL10201217 0.87 HDAC3 (0.51) CRACR2ANPY5RIL2HDAC3HDAC4
SCHEMBL10201238 0.85 STIM1 (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10201231 0.84 STIM1 (0.47) CRACR2ANPY5RIL2HDAC3HDAC4
SCHEMBL10201242 0.81 KLKB1 (0.44) KDM4EALDH1A1RAB9ASTIM1ORAI1
SCHEMBL10201250 0.79 SMN1; SMN2 (0.45) KDM4EALDH1A1RAB9AP2RY1
SCHEMBL10201226 0.78 HDAC3 (0.48) CRACR2ANPY5RIL2HDAC3HDAC4
SCHEMBL15983151 0.77 CRACR2A (0.48) CRACR2ANPY5RHDAC1ALDH1A1STIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10336738-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2019-07-02 US disclosed
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2015-12-03 US disclosed
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2015-12-03 US disclosed
US-9079891-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-07-14 US disclosed
US-9079891-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-07-14 US disclosed
US-20120053210-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2012-03-01 US disclosed
WO-2012027710-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2012-03-01 WO disclosed
US-20120053210-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336738-B2 Compounds that modulate intracellular calcium ORAI1, SARAF, RYR2 CRACR2A 183/4885NPY5R 2598/4885IL2 3716/4885
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 CRACR2A 183/4885NPY5R 2598/4885IL2 3716/4885
US-20120053210-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 CRACR2A 183/4885NPY5R 2598/4885IL2 3716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.